Aspect Biosystems
About Aspect Biosystems
Aspect Biosystems is a biotechnology company pioneering bioprinted tissue therapeutics with a full-stack platform that combines AI-powered bioprinting, computational design tools, therapeutic cells, and advanced biomaterials to create allogeneic tissue therapeutics. The company focuses on regenerative medicine and developing implantable tissues to replace, repair, or augment biological functions for metabolic and endocrine diseases. Its work spans technology development, therapeutic programs, and partnerships with pharma and biotech leaders to bring tissue-based therapies to the clinic, with a global, collaborative approach.
Recent News
Feds Invest $79 Million in Aspect Biosystems to Develop 3D-Printed Tissue Treatment
Aspect Biosystems and Novo Nordisk – Enter New Phase of Partnership to Develop Curative Medicines for Diabetes
MaRS Impact Health Returns to Showcase Canada’s Next Big Healthcare Breakthroughs
Aspect Biosystems Gets $79M From Canadian Government for Diabetes Cell Therapy